Trial Profile
A phase I trial of the combination of sirolimus and SU11248 (Sutent(R)) [sunitinib] in patients with advanced solid tumors that are non-curable with standard therapy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 21 Dec 2013 Status changed from active, no longer recruiting to discontinued.
- 03 Oct 2008 Planned end date changed from 1 Oct 2008 to 1 Dec 2008.
- 22 Jan 2008 Status change